Fubotv earnings beat by $0.10, revenue topped estimates
On Monday, JMP Securities maintained a positive outlook on Prelude Therapeutics (NASDAQ:PRLD), with analyst Reni Benjamin affirming both the Market Outperform rating and the $4.00 price target for the company’s shares. According to InvestingPro data, the stock has shown strong momentum with a 16.71% return over the past week, despite being down 78% year-over-year. The company, which appears undervalued based on InvestingPro’s Fair Value analysis, continues to make strides in cancer treatment by developing PRT3789 and PRT7732, both targeting the synthetic lethality pathway via SMARCA2 degradation.
Prelude’s intravenous candidate, PRT3789, has shown potential efficacy primarily in gastrointestinal cancers, including esophageal and gastric types. The company has observed preclinical synergistic activity when PRT3789 is combined with the chemotherapy agent docetaxel. While InvestingPro analysis shows the company is quickly burning through cash, it maintains a healthy balance sheet with more cash than debt and a current ratio of 5.3x. Market watchers are anticipating the initial data from this combination therapy, which is expected to be released in the second half of 2025.
Additionally, the first-in-human data for Prelude’s oral SMARCA2 degrader, PRT7732, is also projected to become available in the latter half of 2025. These upcoming data readouts are highly anticipated as they will provide insights into the efficacy and potential of Prelude’s novel treatments in the competitive landscape of cancer therapeutics.
JMP Securities highlighted that the expectations for these two significant data readouts, along with Prelude’s competitive position and future plans, will be key topics of discussion in the industry. The continued endorsement from JMP Securities reflects confidence in Prelude’s research and development trajectory as it progresses through these critical stages.
In other recent news, Prelude Therapeutics reported its fourth-quarter 2024 financial results, concluding the period with a cash reserve of $133.6 million. The company is advancing two assets through clinical trials, with initial monotherapy results for PRT3789 showing modest efficacy. JMP Securities has maintained its Market Outperform rating on Prelude Therapeutics, with a price target set at $4.00. The analysts noted the potential of PRT3789 as a candidate for combination therapy, observing objective responses in patients with upper gastrointestinal tract tumors. They are anticipating more data in the second half of 2025, which will aid in reassessing market models. Additionally, Prelude Therapeutics saw a significant insider buying activity, with CEO Vaddi Krishna and Chief Chemistry Officer Andrew Combs purchasing substantial shares. Krishna acquired 675,000 shares, while Combs bought 100,000 shares, signaling confidence from the company’s top executives. These recent developments have resonated positively with investors, reflecting potential optimism for Prelude’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.